Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 89-94

  Masuda, Norikazu ^a   Nakayama, Takahiro ^b   Yamamura, Jun ^a   Kamigaki, Shunji ^c   Taguchi, Tetsuya ^b   Hatta, Mai ^d   Sakamoto, Junichi ^d  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Combination chemotherapy; Cyclophosphamide; Phase I; Weekly paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; TREATMENT OUTCOME;

EID: 77951922017     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1137-z     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942
2. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058-1067
3. Giordano SH (2006) 2006 ASCO annual meeting (abstract #521)
4. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867 (Pubitemid 26185461)
5. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10967 multicenter phase III trial. J Clin Oncol 20:3114-3121
6. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, Central and Eastern Europe, Israel Paclitaxel Breast Cancer Study Group (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as firstline therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715
7. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411
8. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
9. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, 303 Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354 (Pubitemid 29368232)
10. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588-592
11. Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364
12. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671
13. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
14. Verrill MW, Lee J, Cameron DA (2007) Anglo-Celtic IV: first results of a UK National Research Network randomized phase III pharmacogenetic trial of weekly versus 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). In: 2007 ASCO annual meeting (abstract #LBA1005)
15. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387
16. Matsunami N, Masuda N, Morimoto T, Nakayama T, Nomura T, Ishitobi M, Kamigaki S, Yamamura J, Tsukamoto F, Ohashi Y, Taguchi T, Tsujinaka T (2008) Feasibility study of combination therapy with docetaxel and cyclophosphamide for breast cancer in Japan (in Japanese). In: 16th Annual meeting of the Japanese breast cancer society (abstract #O-217)
17. Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8:655-661 (Pubitemid 27372163)
18. Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O'Shaughnessy JA (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14:95-102 (Pubitemid 26020001)
19. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14:783-791
20. Sessa C, Pagani O, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. Semin Oncol 24 (Suppl 17):S17-52-S17-57
21. Nokihara H, Tamura T, Matsumoto Y (2002) Weekly paclitaxel in solid tumor, a phase I trial. 43rd The Japan Lung Cancer Society annual meeting (abstract #E-13). Jpn J Lung Cancer 42:395 (in Japanese)
22. Shulman L (2009) Phase III randomized study of adjuvant cyclophosphamide and doxorubicin versus single-agent paclitaxel in women with operable breast cancer and 0-3 positive axillary lymph nodes. http://www.cancer.gov/search/ viewclinicaltrials.aspx?version=healthprofessional&cdrid=69444. Accessed 26 Aug. 2009
23. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308-1314
24. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849
25. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 6:4610-4617
26. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776-3782
27. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564-3568
28. Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665-685